GLPG-5101

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameGLPG-5101
Drug Alias NameGLPG510119-CP-0219CP02
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Memory T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellPoint BVGalapagos Nv
China Registration ClassN/A

Develop Information

Active CompaniesCellPoint BVCatalent IncGalapagos Nv
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A